Results 121 to 130 of about 47,543 (305)

Nanoparticle polymeric micellar paclitaxel compared with paclitaxel for advanced esophageal squamous cell carcinoma

open access: yesPrecision Medical Sciences, EarlyView.
The nanoparticle polymeric micellar paclitaxel plus nedaplatin regimen demonstrates superior efficacy and tolerable toxicities compared to the paclitaxel–nedaplatin combination as a first‐line treatment for advanced esophageal squamous cell carcinoma.
Yu‐Qing Cao   +7 more
wiley   +1 more source

A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer.

open access: yesPLoS ONE, 2015
BACKGROUND:Concurrent chemoradiotherapy is a standard treatment for local advanced esophageal cancer, but the outcomes are controversial. Our goals were to compare the therapeutic effects of concurrent chemoradiotherapy and radiotherapy alone in local ...
Li-Li Zhu   +12 more
doaj   +1 more source

Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma

open access: yesChinese Journal of Cancer, 2016
The value of adding induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) for the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear.
Wen-Fei Li, Lei Chen, Ying Sun, Jun Ma
doaj   +1 more source

Coronary artery calcium score on standard of care oncologic CT scans for the prediction of adverse cardiovascular events in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy [PDF]

open access: gold, 2022
Efstratios Koutroumpakis   +14 more
openalex   +1 more source

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

open access: yesPrecision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song   +5 more
wiley   +1 more source

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer [PDF]

open access: yes, 2017
To complement the existing treatment guidelines, ESMO organises consensus conferences to focus on specific issues. The 2nd ESMO Consensus Conference on Lung Cancer included 35 experts who met to address several questions on non-small-cell lung cancer ...
Adjei, Alex   +79 more
core  

Calycosin Targets the CYP1B1‐AKT/SP1‐GPX4 Axis to Modulate Ferroptosis in Colorectal Carcinogenesis

open access: yesPhytotherapy Research, EarlyView.
Mechanism of Calycosin in Regulating Ferroptosis in Colorectal Cancer via Binding to CYP1B1. ABSTRACT Calycosin, a natural flavonoid small‐molecule compound derived from traditional Chinese medicine, has demonstrated remarkable pharmacological activity in the field of cancer therapy.
Lihan Bie   +9 more
wiley   +1 more source

Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma

open access: yesCancer Communications, 2019
The standard of care for patients with locoregionally advanced nasopharyngeal carcinoma is concurrent platinum-based chemoradiotherapy. Existing literature have demonstrated that the addition of gemcitabine and cisplatin as induction chemotherapy in ...
Yuan Zhang, Ying Sun, Jun Ma
doaj   +1 more source

A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10‐year outcomes for efficacy and toxicity [PDF]

open access: bronze, 2017
Anne W.M. Lee   +12 more
openalex   +1 more source

Tumour‐informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients post‐treatment

open access: yesVIEW, EarlyView.
Our study presents a tumour‐informed circulating tumour DNA (ctDNA) workflow designed to enhance the detection of recurrence in head and neck cancer patients, addressing key challenges such as low ctDNA tumour fractions and tumour heterogeneity. Abstract Circulating tumour DNA (ctDNA) is a promising minimally invasive biomarker for monitoring treatment
Xiaomin Huang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy